This site is intended for US health care professionals.
01. Foundational / Icons / 32x32px/Menu @1x Open Menu 01. Foundational / Icons / 32x32px/Close @1x Close Menu
Actor Portrayal

Complete the regimen with a 2nd dose of VARIVAX® (Varicella Virus Vaccine Live)

There is an opportunity to improve vaccination rates among teenagers.

9.2%9.2%

of teens still have not received their CDC-recommended 2nd dose of varicella vaccine1,a

CDC recommendations for catch-up dosing2

Ensure persons 7-18 years of age without evidence of immunity have received 2 doses of varicella vaccine:

Ages 7-12
routine interval 3 months
Ages 13 and older
routine interval 4-8 weeks (minimum interval: 4 weeks)

aData from a 2023 Centers for Disease Control and Prevention (CDC) national survey (N=16,568 adolescents) showed that an estimated 90.8% of teens aged 13 to 17 years with no history of chickenpox had received at least 2 doses of varicella vaccine. The CDC analyzed data from the National Immunization Survey (NIS)-Teen to estimate adolescent vaccination coverage in the United States. Immunization data were collected through telephone interviews via randomly selected numbers and confirmed through records supplied by the adolescents’ health care providers. Adolescents in the 2023 NIS-Teen were born during January 2005 through December 2010. Vaccination coverage estimates include only adolescents who had adequately completed provider-reported immunization records.1

References

  1. Pingali C, Yankey D, Elam-Evans LD, et al. National vaccination coverage among adolescents aged 13-17 years – National Immunization Survey-Teen, United States, 2023. MMWR Morb Mortal Wkly Rep. 2024;73:708-714. doi:10.15585/mmwr.mm7333a1
  2. Recommended child and adolescent immunization schedule for ages 18 years or younger, United States, 2025. Updated July 2, 2025. Accessed July 8, 2025. https://www.cdc.gov/vaccines/hcp/imz-schedules/downloads/child/0-18yrs-child-combined-schedule.pdf

Indications and Usage

VARIVAX is a vaccine indicated for active immunization for the prevention of varicella in individuals 12 months of age or older.

Selected Safety Information

  • Do not administer VARIVAX to individuals with: a history of anaphylactic or severe allergic reaction to any component of the vaccine (including neomycin and gelatin) or to a previous dose of a varicella-containing vaccine; immunosuppressed or immunodeficient individuals; an active febrile illness; active untreated tuberculosis; or those who are pregnant or planning to become pregnant in the next 3 months.
  • Vaccination should be deferred in individuals with a family history of immunodeficiency until it can be confirmed the individual is immunocompetent. Vaccine recipients should avoid close contact with high-risk individuals susceptible to varicella due to possible risk of transmission. Varicella vaccine virus transmission may occur between vaccine recipients and contacts susceptible to varicella including healthy individuals. Immune Globulins and other blood products should not be given concomitantly with VARIVAX. Avoid use of salicylates for 6 weeks following administration of VARIVAX to children and adolescents.
  • Frequently reported (≥10%) adverse reactions for subcutaneous injections in children ages 1 to 12 years who were monitored for 42 days include: injection-site complaints: 19.3%; fever ≥102.0°F (38.9°C) oral: 14.7%. Frequently reported (≥10%) adverse reactions for subcutaneous injections in adolescents and adults ages 13 years and older monitored for up to 42 days include: injection-site complaints: 24.4%; fever ≥100.0°F (37.8°C) oral: 10.2%. Other reported adverse reactions in all age groups include: varicella-like rash (injection site) and varicella-like rash (generalized).
  • Adverse reactions reported for both subcutaneous and intramuscular injections of VARIVAX include: fever, injection-site reactions (pain/tenderness/soreness, erythema, and swelling); and rash on the body or at the injection site.
  • In a clinical trial involving children who received 2 doses of VARIVAX 3 months apart, the incidence of injection-site clinical complaints (primarily erythema and swelling) observed in the first 4 days following vaccination was slightly higher post-dose 2 (overall incidence 25.4%) than post-dose 1 (overall incidence 21.7%), whereas the incidence of systemic clinical complaints in the 42-day follow-up period was lower post-dose 2 (66.3%) than post-dose 1 (85.8%).
  • VARIVAX may establish latency of varicella zoster virus in immunocompetent individuals, with the potential for later development of herpes zoster.
  • There are insufficient data to assess the rate of protection of VARIVAX against the serious complications of chickenpox in adults (eg, encephalitis, hepatitis, pneumonia), and during pregnancy (congenital varicella syndrome).
  • The duration of protection from varicella infection after vaccination with VARIVAX is unknown.
  • Vaccination with VARIVAX may not result in protection of all healthy, susceptible children, adolescents, and adults.
  • A boost in antibody levels has been observed in vaccinees following exposure to wild-type varicella, which could account for the apparent long-term persistence of antibody levels in these studies.
  • Due to the concern for transmission of vaccine virus, vaccine recipients should attempt to avoid, whenever possible, close association with susceptible high-risk individuals for up to 6 weeks following vaccination.
  • VARIVAX is contraindicated for use in pregnant women because the vaccine contains live, attenuated varicella virus, and it is known that wild-type varicella virus, if acquired during pregnancy, can cause congenital varicella.
  • It is not known whether varicella vaccine virus is excreted in human milk.
  • The long-term effect of VARIVAX on the incidence of herpes zoster, particularly in those vaccinees exposed to wild-type varicella, is unknown at present.

 

Dosage and Administration

  • Each dose is approximately 0.5 mL and is administered intramuscularly or subcutaneously.
    • Children (12 months to 12 years of age):  The first dose is administered between 12 and 15 months of age. The second dose is administered between 4 to 6 years of age. There should be a minimum interval of 3 months between doses.
    • Adolescents (≥13 years of age) and Adults: Two doses are administered with a minimum interval of 4 weeks between doses.

Before administering VARIVAX, please read the accompanying Prescribing Information. The Patient Information also is available.

Indications and Usage
Selected Safety Information

VARIVAX is a vaccine indicated for active immunization for the prevention of varicella in individuals 12 months of age or older.

Selected Safety Information

  • Do not administer VARIVAX to individuals with: a history of anaphylactic or severe allergic reaction to any component of the vaccine (including neomycin and gelatin) or to a previous dose of a varicella-containing vaccine; immunosuppressed or immunodeficient individuals; an active febrile illness; active untreated tuberculosis; or those who are pregnant or planning to become pregnant in the next 3 months.
  • Vaccination should be deferred in individuals with a family history of immunodeficiency until it can be confirmed the individual is immunocompetent. Vaccine recipients should avoid close contact with high-risk individuals susceptible to varicella due to possible risk of transmission. Varicella vaccine virus transmission may occur between vaccine recipients and contacts susceptible to varicella including healthy individuals. Immune Globulins and other blood products should not be given concomitantly with VARIVAX. Avoid use of salicylates for 6 weeks following administration of VARIVAX to children and adolescents.
  • Frequently reported (≥10%) adverse reactions for subcutaneous injections in children ages 1 to 12 years who were monitored for 42 days include: injection-site complaints: 19.3%; fever ≥102.0°F (38.9°C) oral: 14.7%. Frequently reported (≥10%) adverse reactions for subcutaneous injections in adolescents and adults ages 13 years and older monitored for up to 42 days include: injection-site complaints: 24.4%; fever ≥100.0°F (37.8°C) oral: 10.2%. Other reported adverse reactions in all age groups include: varicella-like rash (injection site) and varicella-like rash (generalized).
  • Adverse reactions reported for both subcutaneous and intramuscular injections of VARIVAX include: fever, injection-site reactions (pain/tenderness/soreness, erythema, and swelling); and rash on the body or at the injection site.
  • In a clinical trial involving children who received 2 doses of VARIVAX 3 months apart, the incidence of injection-site clinical complaints (primarily erythema and swelling) observed in the first 4 days following vaccination was slightly higher post-dose 2 (overall incidence 25.4%) than post-dose 1 (overall incidence 21.7%), whereas the incidence of systemic clinical complaints in the 42-day follow-up period was lower post-dose 2 (66.3%) than post-dose 1 (85.8%).
  • VARIVAX may establish latency of varicella zoster virus in immunocompetent individuals, with the potential for later development of herpes zoster.
  • There are insufficient data to assess the rate of protection of VARIVAX against the serious complications of chickenpox in adults (eg, encephalitis, hepatitis, pneumonia), and during pregnancy (congenital varicella syndrome).
  • The duration of protection from varicella infection after vaccination with VARIVAX is unknown.
  • Vaccination with VARIVAX may not result in protection of all healthy, susceptible children, adolescents, and adults.
  • A boost in antibody levels has been observed in vaccinees following exposure to wild-type varicella, which could account for the apparent long-term persistence of antibody levels in these studies.
  • Due to the concern for transmission of vaccine virus, vaccine recipients should attempt to avoid, whenever possible, close association with susceptible high-risk individuals for up to 6 weeks following vaccination.
  • VARIVAX is contraindicated for use in pregnant women because the vaccine contains live, attenuated varicella virus, and it is known that wild-type varicella virus, if acquired during pregnancy, can cause congenital varicella.
  • It is not known whether varicella vaccine virus is excreted in human milk.
  • The long-term effect of VARIVAX on the incidence of herpes zoster, particularly in those vaccinees exposed to wild-type varicella, is unknown at present.

 

Dosage and Administration

  • Each dose is approximately 0.5 mL and is administered intramuscularly or subcutaneously.
    • Children (12 months to 12 years of age):  The first dose is administered between 12 and 15 months of age. The second dose is administered between 4 to 6 years of age. There should be a minimum interval of 3 months between doses.
    • Adolescents (≥13 years of age) and Adults: Two doses are administered with a minimum interval of 4 weeks between doses.

Before administering VARIVAX, please read the accompanying Prescribing Information. The Patient Information also is available.